Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Online ISSN 1827-1669
Ni X. 1, Qi S. 2
1 Shenzhen Second People’s hospital, (The First Affiliated Hospital of Shenzhen University), Shenzhen, Guangdong, P.R. China;
2 National-Reginoal Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, Department of Biomedical Engineering Medical School, Shenzhen University, Guangdong, P.R. China
Aim: The aim of this paper was to validate the use of the chemiluminescence immunoassay (CLIA) for detecting the squamous cell carcinoma antigen (SCCa) in human serum or plasma using a Maglumi 2000 automatic analyzer.
Methods: We performed a pilot study to examine both the sensitivity and specificity of the SCCa, in diagnosing squamous cell carcinomas. High levels of SCCa are helpful in diagnosing lung cancer, especially squamous cell carcinoma.
Results: The method was linear to 22.81 ng/mL SCCa, with a detection limit of 0.02 ng/mL. An entire assay can be completed in 40 mins. The coefficients of variation (CV) of the intra- and inter-assays were less than 5% and 6%, respectively. There was a good correlation between the present and manual method. The SCCa discriminated between the squamous cell carcinoma patients and healthy controls with an area under the receiver operating characteristic (ROC) curve of 0.9231.
Conclusion: These results indicate that the SCCa assay showed good performance using a Maglumi 2000 automatic analyzer. This new and simple analytic system will promote the application of SCCa in clinical laboratories.